The global Varicella Vaccines Market is experiencing a significant surge, fueled by growing awareness of the vaccine’s importance in preventing chickenpox. According to recent market data, the market jumped from USD 2.93 billion in 2021 to USD 3.11 billion in 2022, marking a substantial 6.1% year-over-year increase. This upward trend is expected to continue, with the market projected to reach a remarkable USD 5.76 billion by 2032, driven by a Compound Annual Growth Rate (CAGR) of 6.3%.
The driving force behind this remarkable growth is the global surge in initiatives combatting infectious diseases, with a particular focus on addressing chickenpox and measles. Governments across the world are escalating their efforts to control and prevent the prevalence of these diseases, leading to an unprecedented demand for varicella vaccines.
Request a Sample of this Report Now Use Work Mail to Get Quick Reply!
From 2015 to 2021, the market flourished significantly, reaching US$ 2.93 Billion by the end of the said historical period. The Chickenpox segment is likely to offer remunerative opportunities for the Global Varicella Vaccines Industry. Several emerging economies are making significant developments in their healthcare sector, thereby, providing lucrative opportunities to players in the market.
Varicella Vaccines Market Key Takeaways:
- Global Varicella Vaccines Industry to surpass US$ 3 Billion in value by 2022-end
- By application, chickenpox immunization is expected to record a 7.1% CAGR until 2032
- By product, monovalent vaccines contributed 73.2% of the total market value in 2021
- North America is the fastest-growing market, registering a 6.7% value CAGR
- South Asia to be the most opportunistic market, accumulating a market value of US$ 320 Million by 2032
- China to be a key contributor in the East Asian market, growing at a 5.9% CAGR
Varicella Vaccines Market Competitive Landscape
Eminent players in the Global Varicella Vaccines Industry include Bio-Med Pvt. Limited, Pfizer Inc., Emcure Pharmaceuticals Limited, Merck & Co Inc., Sanofi, and Novo Medi Sciences among others. Recent key developments among players include:
- In January 2022 – Pfizer Inc. and BioNTech SE announced a new research, development, and commercialization collaboration to develop a potential first mRNA-based vaccine for the prevention of shingles (herpes zoster virus, or HZV) a debilitating, disfiguring, and painful disease that impacts about one in three people in the United States during their lifetime. This is the third collaboration between Pfizer and BioNTech in the infectious diseases field.
- In July 2021 - GC LabCell and GC Cell announced a merger agreement to combine in an all-stock transaction. The transaction brings together two iconic South Korean biopharmaceutical companies, highly complementary portfolios with a robust broad cell therapy R&D pipeline and cutting-edge manufacturing capabilities to accelerate growth and enhance value creation.
More Valuable Insights
In its new offering, Future Market Insights presents an unbiased analysis of the Global Varicella vaccine industry, presenting a historical analysis from 2015 to 2021 and forecast statistics for 2022-2032.
The study reveals essential insights based on product (monovalent, combination) by application (chickenpox immunization, herpes zoster immunization, mumps, measles, and rubella & varicella (MMRV) immunization) and by end-user (hospitals, clinics, and others), across seven major regions (North America, Europe, South Asia, East Asia, Oceania, Middle East & Africa, and Latin America)
Key Segments Covered in the Varicella Vaccines Industry Survey
by Product:
- Monovalent Varicella Vaccines
- Combination Varicella Vaccines
by Application:
- Varicella Vaccines for Chickenpox Immunization
- Varicella Vaccines for Herpes Zoster Immunization
- Varicella Vaccines for Mumps, measles, rubella & varicella (MMRV) Immunization
by End User:
- Varicella Vaccines for Hospitals
- Varicella Vaccines for Clinics
- Varicella Vaccines for Other End Users
by Region:
- North America Varicella Vaccines Market
- Europe Varicella Vaccines Market
- South Asia Varicella Vaccines Market
- East Asia Varicella Vaccines Market
- Oceania Varicella Vaccines Market
- Middle East & Africa Varicella Vaccines Market
- Latin America Varicella Vaccines Market
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges clients face and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI is the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube